Insurers are under pressure to modernize core systems while competing for scarce cloud, data, AI, and cybersecurity talent. Info-Tech Research Group’s new blueprint, Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance, outlines a practical framework to help insurance IT and HR leaders assess readiness, strengthen their employee value proposition, and retain the critical roles needed to accelerate transformation.

ARLINGTON, Va., May 8, 2026 /PRNewswire/ – Insurance modernization is increasingly being constrained by the people and capabilities required to deliver it, according to Info-Tech Research Group. The global research and advisory firm’s newly published blueprint, Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance, provides a structured approach to help insurers attract, retain, and mobilize the IT talent required to support digital transformation.

The firm’s research indicates that many insurers are trying to advance core system modernization while facing shortages in cloud, data, AI, and cybersecurity roles. At the same time, experienced legacy system experts are retiring, creating knowledge gaps that can slow delivery, increase operational risk, and deepen dependence on external partners.

“Insurance modernization cannot succeed if the workforce strategy behind it remains outdated,” says Vidhi Trivedi, senior research analyst at Info-Tech Research Group. “Insurers need an employee value proposition that reflects what both digital and legacy talent value today: flexibility, growth, purpose, and belonging. When organizations connect those expectations to the technology roadmap, they are better positioned to retain institutional knowledge, attract new capabilities, and move transformation forward with confidence.”

Key Workforce Risks Slowing Insurance Modernization

Info-Tech’s blueprint identifies several talent challenges that are limiting insurers’ ability to modernize effectively:

Critical digital skills remain difficult to attract and retain. Cloud engineers, data architects, cybersecurity specialists, and AI-capable technologists are essential to future-state systems, integration, and automation.Legacy expertise is leaving faster than it can be replaced. Core system knowledge remains vital to operations, compliance, and transition planning, yet many long-tenured experts are approaching retirement or feel disconnected from future-state roles.Rigid work models reduce access to high-demand talent. Digital professionals increasingly expect hybrid options, autonomy, modern delivery practices, and environments that support productivity and wellbeing.Growth pathways are not clearly connected to transformation needs. Without structured upskilling, internal mobility, and role progression, insurers risk losing employees to industries perceived as more innovative or career-accelerating.Employer branding often undersells insurance’s purpose and impact. The industry plays a critical role in protecting people, businesses, and communities, but that purpose is not always translated into a compelling technology career story.

Info-Tech’s Three-Phase Framework for Rebuilding the Insurance IT Talent Engine

To help insurers address these challenges, the Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint outlines a three-phase methodology:

Assess Talent Readiness for Modernization Success
Insurance IT and HR leaders identify modernization-critical roles, evaluate workforce pressure, assess EVP fit across key roles, and prioritize the roles that pose the greatest risk to transformation timelines.Build and Embed a Modern Employee Value Proposition
Organizations define a clear employer-employee value exchange, establish proof points across the four EVP pillars of flexibility, growth, purpose, and belonging, and activate targeted initiatives for priority roles.Develop and Present the EVP Impact Report
Leaders synthesize workforce insights, visualize progress, and present a measurable view of how EVP activation is improving retention, engagement, internal mobility, and readiness.

The resource also includes supporting tools, such as the EVP Diagnostic Tool, EVP Activation & Implementation Tool, and EVP Impact Report Template, that help insurers move from talent planning to measurable action.

“Too often, insurers view IT talent challenges as a capacity issue, when they are really a transformation risk,” explains Trivedi. ” “The insurers that move fastest will be those that know where critical capabilities are under strain, protect the expertise that increases operational resilience, and create clear pathways for employees to help shape the future of insurance from within.”

By applying Info-Tech’s framework outlined in the Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint, insurance leaders can better understand where people-related risks are highest, strengthen retention in critical roles, reduce long-term reliance on external partners, and build a more resilient technology organization. The firm’s research emphasizes that a modern EVP is not only an HR initiative but a strategic enabler of modernization success.

For exclusive and timely commentary from Info-Tech’s experts, including Vidhi Trivedi, and access to the complete Rebuild Your Talent Engine: Attract and Retain IT Talent in Insurance blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/insurance-modernization-at-risk-as-workforce-strategies-fall-behind-says-info-tech-research-group-302767354.html

SOURCE Info-Tech Research Group

IRVING, Texas, May 8, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.

Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).

The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality systems, personnel qualifications and compliance with applicable state regulations.

“Caris is committed to meeting the highest standards for laboratory quality, validation and regulatory compliance,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “This submission of Caris Assure for review through the New York State Department of Health’s Wadsworth Center reflects our disciplined approach to expanding access to our technologies in a manner that demonstrates the rigor, responsibility and focus on the patient that define Caris Life Sciences and guide our work in the markets we serve.”

At this time, no determination has been made by NYSDOH, and Caris Assure is not authorized for use on blood-based specimens originating from New York State unless and until CLEP authorization is granted.

Caris operates a CAP-accredited, CLIA‑certified clinical laboratory and performs testing in jurisdictions where it is authorized to do so, in accordance with all applicable federal, state, and local regulations. Any future availability of Caris Assure in New York State will be contingent upon completion of the CLEP review process administered by the Wadsworth Center and receipt of the appropriate authorization.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-submits-application-to-new-york-state-department-of-health-for-caris-assure-bloodbased-testing-authorization-302767104.html

SOURCE Caris Life Sciences

DOWNERS GROVE, Ill., May 8, 2026 /PRNewswire/ — The Board of Directors of Dover Corporation (NYSE: DOV) today declared a regular quarterly cash dividend of $0.52 (fifty-two cents) per share, payable on June 15, 2026, to shareholders of record as of May 29, 2026.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what’s possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under “DOV.” Additional information is available at dovercorporation.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dover-declares-regular-quarterly-cash-dividend-302767309.html

SOURCE Dover